These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
122 related items for PubMed ID: 11078366
1. Effects of endothelin-converting enzyme inhibitors on hemolysate-induced morphological changes and production of endothelin-1 in bovine cerebrovascular endothelial cells. Kwan AL, Lin CL, Chang CZ, Winardi D, Yen CP, Howng SL, Jeng AY. J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S160-2. PubMed ID: 11078366 [Abstract] [Full Text] [Related]
6. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells. Pelletier S, Battistini B, Jeng AY, Sirois P. J Cardiovasc Pharmacol; 1998 Nov; 31 Suppl 1():S10-2. PubMed ID: 9595386 [Abstract] [Full Text] [Related]
7. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat. Dai ZK, Hsieh CC, Chai CY, Wu JR, Jeng AY, Chou SH, Wu BN, Yeh JL, Chen IJ, Tan MS. Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482 [Abstract] [Full Text] [Related]
12. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor. Shetty SS, Savage P, DelGrande D, De Lombaert S, Jeng AY. J Cardiovasc Pharmacol; 1998 Nov; 31 Suppl 1():S68-70. PubMed ID: 9595403 [Abstract] [Full Text] [Related]
13. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066. Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ. J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S36-9. PubMed ID: 11078330 [Abstract] [Full Text] [Related]
14. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor. Feldman DL, Mogelesky TC, Chou M, Jeng AY. J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S342-5. PubMed ID: 11078415 [Abstract] [Full Text] [Related]
15. Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11. Held HD, Raschak M, Uhlig S. Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):619-24. PubMed ID: 9151301 [Abstract] [Full Text] [Related]
16. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats. Pham D, Jeng AY, Escher E, Sirois P, Battistini B. J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S362-6. PubMed ID: 11078421 [Abstract] [Full Text] [Related]
17. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats. Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY. J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331 [Abstract] [Full Text] [Related]